PBAC's latest decision on Ivabradine: Recommended with restriction (2015). Considered for Chronic heart failure in symptomatic patients (NYHA classes II or III) with reduced left ventricular ejection fraction (≤35%) and elevated resting heart rate (≥77 bpm) on optimal standard heart failure treatment.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
3
first 2011
Submissions
3
2011 → 2015
Eligible population
Adults with chronic heart failure, NYHA classes II or III, in sinus rhythm, with left ventricular ejection fraction ≤35%, resting heart rate ≥77 bpm, receiving optimal standard chronic heart failure treatment including maximum tolerated dose beta-blocker.
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
RCT
Key trials
SHIFT
Economic model
Not modelled
Eligible patients/year
3,293
ICER note
Minor submission; no economic comparison presented.
ICER (historical)
$15k/QALY–$200k/QALY across 2 submissions (2011–2012) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Risk sharing
Risk-sharing arrangement in place — Risk share agreement (RSA) in place; expenditure estimated at 39% below first year RSA threshold.
Submission history
Nov 2011: Not recommended — ICER $45k/QALY
Jul 2012: Not recommended — ICER $200k/QALY
Mar 2015: Recommended with restriction · Authority Required